EP3038652 - COMBINATION OF AN ALK INHIBITOR AND A CDK INHIBITOR FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 25.01.2019 Database last updated on 03.09.2024 | |
Former | The patent has been granted Status updated on 16.02.2018 | ||
Former | Grant of patent is intended Status updated on 16.10.2017 | ||
Former | Request for examination was made Status updated on 19.09.2017 | ||
Former | Grant of patent is intended Status updated on 25.04.2017 | Most recent event Tooltip | 10.07.2020 | Lapse of the patent in a contracting state New state(s): IS | published on 12.08.2020 [2020/33] | Applicant(s) | For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH | [2016/27] | Inventor(s) | 01 /
HARRIS, Jennifer Leslie Novartis Institute for Functional Genomics Inc. dba Genomics Institute of the Novartis Research Foundation 10675 John Jay Hopkins Drive San Diego, California 92121 / US | 02 /
LI, Nanxin Novartis Insitute for Functional Genomics Inc. dba Genomics Institute of the Novartis Research Foundation 10675 John Jay Hopkins Drive San Diego, California 92121 / US | 03 /
SMITH, Timothy R. Novartis Institute for Functional Genomics Inc. dba Genomics Institute of theNovartis Research Foundation 10675 John Jay Hopkins Drive San Diego, California 92121 / US | [2016/27] | Representative(s) | Kristl, Jernej, et al Novartis Pharma AG IP Patent Department Forum 1 Novartis Campus 4056 Basel / CH | [2016/27] | Application number, filing date | 14766301.7 | 28.08.2014 | [2016/27] | WO2014US53244 | Priority number, date | US201361871275P | 28.08.2013 Original published format: US 201361871275 P | [2016/27] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2015031666 | Date: | 05.03.2015 | Language: | EN | [2015/09] | Type: | A1 Application with search report | No.: | EP3038652 | Date: | 06.07.2016 | Language: | EN | The application published by WIPO in one of the EPO official languages on 05.03.2015 takes the place of the publication of the European patent application. | [2016/27] | Type: | B1 Patent specification | No.: | EP3038652 | Date: | 21.03.2018 | Language: | EN | [2018/12] | Search report(s) | International search report - published on: | EP | 05.03.2015 | Classification | IPC: | A61K31/506, A61K31/519, A61K45/06, A61P35/00 | [2017/19] | CPC: |
A61K31/519 (EP,KR,US);
A61K31/506 (EP,KR,US);
A61K45/06 (EP,KR,US);
A61P25/00 (EP);
A61P35/00 (EP);
A61P43/00 (EP);
A61K2300/00 (KR)
(-)
| C-Set: |
A61K31/506, A61K2300/00 (EP,US);
A61K31/519, A61K2300/00 (US,EP) |
Former IPC [2016/27] | A61K45/00, A61K31/506, A61K31/519, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/27] | Extension states | BA | 29.03.2016 | ME | 29.03.2016 | Title | German: | KOMBINATION VON ALK- UND CDK-HEMMERN ZUR BEHANDLUNG ZELLPROLIFERATIVER ERKRANKUNGEN | [2017/19] | English: | COMBINATION OF AN ALK INHIBITOR AND A CDK INHIBITOR FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES | [2016/27] | French: | COMBINAISON D'UN INHIBITEUR D'ALK ET D'UN INHIBITEUR DE CDK POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES CELLULAIRES | [2017/19] |
Former [2016/27] | KOMBINATION EINES ALK-INHIBITORS UND CDK-INHIBITORS ZUR BEHANDLUNG VON ZELLPROLIFERATIVEN ERKRANKUNGEN | ||
Former [2016/27] | COMBINAISON D'UN INHIBITEUR D'ALK ET D'UN INHIBITEUR DE CDK POUR LE TRAITEMENT DE MALADIES CELLULAIRES PROLIFÉRATIVES | Entry into regional phase | 29.03.2016 | National basic fee paid | 29.03.2016 | Designation fee(s) paid | 29.03.2016 | Examination fee paid | Examination procedure | 26.06.2015 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 29.03.2016 | Examination requested [2016/27] | 17.10.2016 | Amendment by applicant (claims and/or description) | 26.04.2017 | Communication of intention to grant the patent | 05.09.2017 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 06.09.2017 | Fee for grant paid | 06.09.2017 | Fee for publishing/printing paid | 17.10.2017 | Communication of intention to grant the patent | 07.02.2018 | Receipt of the translation of the claim(s) | Opposition(s) | 02.01.2019 | No opposition filed within time limit [2019/09] | Fees paid | Renewal fee | 11.08.2016 | Renewal fee patent year 03 | 14.08.2017 | Renewal fee patent year 04 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 28.08.2014 | AL | 21.03.2018 | AT | 21.03.2018 | CY | 21.03.2018 | CZ | 21.03.2018 | DK | 21.03.2018 | EE | 21.03.2018 | FI | 21.03.2018 | HR | 21.03.2018 | LT | 21.03.2018 | LV | 21.03.2018 | MC | 21.03.2018 | MK | 21.03.2018 | NL | 21.03.2018 | PL | 21.03.2018 | RO | 21.03.2018 | RS | 21.03.2018 | SE | 21.03.2018 | SI | 21.03.2018 | SK | 21.03.2018 | SM | 21.03.2018 | TR | 21.03.2018 | BG | 21.06.2018 | NO | 21.06.2018 | GR | 22.06.2018 | IS | 21.07.2018 | PT | 23.07.2018 | IE | 28.08.2018 | LU | 28.08.2018 | MT | 28.08.2018 | BE | 31.08.2018 | CH | 31.08.2018 | LI | 31.08.2018 | [2020/33] |
Former [2020/31] | HU | 28.08.2014 | |
AL | 21.03.2018 | ||
AT | 21.03.2018 | ||
CY | 21.03.2018 | ||
CZ | 21.03.2018 | ||
DK | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
MC | 21.03.2018 | ||
MK | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
RS | 21.03.2018 | ||
SE | 21.03.2018 | ||
SI | 21.03.2018 | ||
SK | 21.03.2018 | ||
SM | 21.03.2018 | ||
TR | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
IE | 28.08.2018 | ||
LU | 28.08.2018 | ||
MT | 28.08.2018 | ||
BE | 31.08.2018 | ||
CH | 31.08.2018 | ||
LI | 31.08.2018 | ||
Former [2020/30] | HU | 28.08.2014 | |
AL | 21.03.2018 | ||
AT | 21.03.2018 | ||
CY | 21.03.2018 | ||
CZ | 21.03.2018 | ||
DK | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
MC | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
RS | 21.03.2018 | ||
SE | 21.03.2018 | ||
SI | 21.03.2018 | ||
SK | 21.03.2018 | ||
SM | 21.03.2018 | ||
TR | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
IE | 28.08.2018 | ||
LU | 28.08.2018 | ||
MT | 28.08.2018 | ||
BE | 31.08.2018 | ||
CH | 31.08.2018 | ||
LI | 31.08.2018 | ||
Former [2020/16] | AL | 21.03.2018 | |
AT | 21.03.2018 | ||
CY | 21.03.2018 | ||
CZ | 21.03.2018 | ||
DK | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
MC | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
RS | 21.03.2018 | ||
SE | 21.03.2018 | ||
SI | 21.03.2018 | ||
SK | 21.03.2018 | ||
SM | 21.03.2018 | ||
TR | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
LU | 28.08.2018 | ||
MT | 28.08.2018 | ||
BE | 31.08.2018 | ||
CH | 31.08.2018 | ||
LI | 31.08.2018 | ||
Former [2020/08] | AL | 21.03.2018 | |
AT | 21.03.2018 | ||
CY | 21.03.2018 | ||
CZ | 21.03.2018 | ||
DK | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
MC | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
RS | 21.03.2018 | ||
SE | 21.03.2018 | ||
SI | 21.03.2018 | ||
SK | 21.03.2018 | ||
SM | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
LU | 28.08.2018 | ||
MT | 28.08.2018 | ||
BE | 31.08.2018 | ||
CH | 31.08.2018 | ||
LI | 31.08.2018 | ||
Former [2019/38] | AL | 21.03.2018 | |
AT | 21.03.2018 | ||
CY | 21.03.2018 | ||
CZ | 21.03.2018 | ||
DK | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
MC | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
RS | 21.03.2018 | ||
SE | 21.03.2018 | ||
SI | 21.03.2018 | ||
SK | 21.03.2018 | ||
SM | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
LU | 28.08.2018 | ||
BE | 31.08.2018 | ||
CH | 31.08.2018 | ||
LI | 31.08.2018 | ||
Former [2019/26] | AL | 21.03.2018 | |
AT | 21.03.2018 | ||
CY | 21.03.2018 | ||
CZ | 21.03.2018 | ||
DK | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
MC | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
RS | 21.03.2018 | ||
SE | 21.03.2018 | ||
SI | 21.03.2018 | ||
SK | 21.03.2018 | ||
SM | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
LU | 28.08.2018 | ||
CH | 31.08.2018 | ||
LI | 31.08.2018 | ||
Former [2019/21] | AL | 21.03.2018 | |
AT | 21.03.2018 | ||
CY | 21.03.2018 | ||
CZ | 21.03.2018 | ||
DK | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
MC | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
RS | 21.03.2018 | ||
SE | 21.03.2018 | ||
SK | 21.03.2018 | ||
SM | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
LU | 28.08.2018 | ||
CH | 31.08.2018 | ||
LI | 31.08.2018 | ||
Former [2019/15] | AL | 21.03.2018 | |
AT | 21.03.2018 | ||
CY | 21.03.2018 | ||
CZ | 21.03.2018 | ||
DK | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
MC | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
RS | 21.03.2018 | ||
SE | 21.03.2018 | ||
SK | 21.03.2018 | ||
SM | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
Former [2019/08] | AL | 21.03.2018 | |
AT | 21.03.2018 | ||
CY | 21.03.2018 | ||
CZ | 21.03.2018 | ||
DK | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
RS | 21.03.2018 | ||
SE | 21.03.2018 | ||
SK | 21.03.2018 | ||
SM | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
Former [2019/03] | AL | 21.03.2018 | |
AT | 21.03.2018 | ||
CY | 21.03.2018 | ||
CZ | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
RS | 21.03.2018 | ||
SE | 21.03.2018 | ||
SK | 21.03.2018 | ||
SM | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
PT | 23.07.2018 | ||
Former [2018/52] | AL | 21.03.2018 | |
AT | 21.03.2018 | ||
CY | 21.03.2018 | ||
CZ | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
RS | 21.03.2018 | ||
SE | 21.03.2018 | ||
SK | 21.03.2018 | ||
SM | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
Former [2018/50] | AL | 21.03.2018 | |
AT | 21.03.2018 | ||
CY | 21.03.2018 | ||
CZ | 21.03.2018 | ||
EE | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
NL | 21.03.2018 | ||
PL | 21.03.2018 | ||
RO | 21.03.2018 | ||
RS | 21.03.2018 | ||
SE | 21.03.2018 | ||
SK | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
Former [2018/46] | AL | 21.03.2018 | |
CY | 21.03.2018 | ||
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
NL | 21.03.2018 | ||
RS | 21.03.2018 | ||
SE | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
Former [2018/45] | CY | 21.03.2018 | |
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
NL | 21.03.2018 | ||
RS | 21.03.2018 | ||
SE | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
Former [2018/40] | CY | 21.03.2018 | |
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
LV | 21.03.2018 | ||
RS | 21.03.2018 | ||
SE | 21.03.2018 | ||
BG | 21.06.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
Former [2018/37] | CY | 21.03.2018 | |
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
NO | 21.06.2018 | ||
GR | 22.06.2018 | ||
Former [2018/35] | CY | 21.03.2018 | |
FI | 21.03.2018 | ||
HR | 21.03.2018 | ||
LT | 21.03.2018 | ||
NO | 21.06.2018 | Cited in | International search | [YD]WO2008073687 (IRM LLC, et al) [YD] 1-21 * pages 17-18, paragraph [0040] * * claims 1, , 6, 11, 17-20 * * compounds 66, 231 *; | [YD]WO2010020675 (NOVARTIS AG [CH], et al) [YD] 1-21 * page 11, paragraph 4 * * page 19, paragraph l - page 20, paragraph 1 * * page 21, paragraph 2 - page 22, paragraph 3 * * page 27, paragraph 2 * * page 45, paragraph 3 - page 46, paragraph 3 * * page 178; example 74 * * claims 1, 13 *; | [Y]WO2012106540 (IRM LLC [US], et al) [Y] 1,2,4-21 * page 1, paragraph [0004] * * page 2, paragraph [0007]; compound 1 * * claims 1, 6 *; | [XY] - P. BONVINI ET AL, "The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity", HAEMATOLOGICA, (20090616), vol. 94, no. 7, doi:10.3324/haematol.2008.004861, ISSN 0390-6078, pages 944 - 955, XP055144707 [X] 1,4,5,8-14,16,19-21 * abstract * * page 945, column 1, paragraph 2 * * figure 5 * * page 952, column 2, paragraph 2 - page 953, column 2, paragraph 1 * * page 954, column 1, paragraph 2 - column 2, paragraph 1 * [Y] 1-21 DOI: http://dx.doi.org/10.3324/haematol.2008.004861 | [Y] - THOMAS H. MARSILJE ET AL, "Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro- N 2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)- N 4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Pha", JOURNAL OF MEDICINAL CHEMISTRY, (20130725), vol. 56, no. 14, doi:10.1021/jm400402q, ISSN 0022-2623, pages 5675 - 5690, XP055145299 [Y] 1,2,4-21 * abstract * * page 5675, column 1, paragraph 2 - column 2, paragraph 2 * * figure 1 * * table 4 * * page 5681, column 1, paragraph 1 * * page 5682, column 2, paragraph 1 - page 5683, column 1, paragraph 1 * DOI: http://dx.doi.org/10.1021/jm400402q | [Y] - ROBERT ROSKOSKI, "Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition", PHARMACOLOGICAL RESEARCH, (20130201), vol. 68, no. 1, doi:10.1016/j.phrs.2012.11.007, ISSN 1043-6618, pages 68 - 94, XP055145296 [Y] 11-18 * abstract * * page 76, column 2, paragraph 3 * * tables 3, 4 * * page 77, column 2, paragraph 2 * * page 78, column 1, paragraph 4 * * page 81, column 1, paragraph 2 * * page 82, column 2, paragraph 1 - page 83, column 1, paragraph 2 * * figure 7 * * page 87, column 2, paragraph 2 * DOI: http://dx.doi.org/10.1016/j.phrs.2012.11.007 | [YP] - BENGT HALLBERG ET AL, "Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology", NATURE REVIEWS CANCER, (20130924), vol. 13, no. 10, doi:10.1038/nrc3580, ISSN 1474-175X, pages 685 - 700, XP055086717 [YP] 1-21 * abstract * * Key points; page 688, column 1, paragraph 1 * * figure 1 * * page 695, column 1, paragraph 2 * * page 696, column 1, paragraph 2 * * page 696, column 2, paragraph 4 * DOI: http://dx.doi.org/10.1038/nrc3580 |